BrightInsight has always lived in the unglamorous basement of digital health, the place where compliance hums, servers sweat, and regulators decide whether your clever idea ever sees daylight....
BrightInsight has always lived in the unglamorous basement of digital health, the place where compliance hums, servers sweat, and regulators decide whether your clever idea ever sees daylight. Founded in San Jose, California in 2017 and publicly launched in 2018, BrightInsight came out of Flex with Kal Patel, MD, MBA, Ferry Tamtoro, and Ben Lee carrying a shared scar tissue from Amgen. They had all watched pharma teams burn months and millions rebuilding the same regulated plumbing over and over. So they spun out a company to make the boring parts lethal and the hard parts faster.
BrightInsight quietly added $13 million in strategic growth capital, and the quiet part is the tell. Eclipse Ventures, General Catalyst, Insight Partners, and New Leaf Venture Partners all came back. Mayo Clinic joined as a new strategic investor. When a healthcare system known for outcomes, not hype, writes a check into infrastructure, that is not curiosity. That is alignment.
BrightInsight does not sell apps. It sells time. FDA validated infrastructure, an accepted Device Master File, and a quality system that lets biopharma move from idea to regulated reality in 6 to 12 months instead of the usual 18 to 24. Built on Google Cloud, certified across ISO 13485, IEC 62304, HITRUST, HIPAA, GDPR, and MDSAP, the platform connects more than 400 medical devices and supports everything from SaMD to combination products without asking customers to relearn compliance every quarter.
The proof lives in the numbers nobody jokes about. In partnership with Sanofi and Regeneron, a BrightInsight powered patient app has been adopted by more than 25,000 patients. Real world data from over 6,000 patients shows a 4% lower therapy discontinuation rate after one year. Participation rates sit between 30 and 70%, with retention holding after twelve months. In a market where half of chronic patients walk away from therapy and non-adherence drives up to $300 billion in waste, four percent is not a rounding error.
Kal Patel is steering this moment with operators who know how to scale without breaking glass. Robert Zdon joined as COO in 2025 to turn data into execution. Ashish Agrawal runs the platform with an enterprise spine. Eric Redline and Leigh Wager arrived in January to push market development and product with discipline. This team is not chasing shine. They are building gravity.
The new capital is flowing into AI driven persistence prediction, disease specific ecosystems, multi stakeholder engagement, and global expansion of the Sanofi partnership. BrightInsight is betting that the future of digital health is not louder software but quieter infrastructure that works. When the pipes hold, outcomes follow, and the industry stops pretending adherence is a mystery instead of a solvable problem.